The blockbuster success of GLP-1 weight loss drugs has caused major ripple effects across healthcare and pharma, representing a significant growth engine for drugmakers but a cost challenge for payers.
GLP-1s also are potentially disrupting a healthcare system built around treating obesity-related complications, forcing providers, insurers and investors to rethink where future revenue and growth will come from, according to a new report from Wells Fargo.
For decades, the healthcare industry has built service lines, reimbursement models and care pathways around the downstream consequences of obesity. Diabetes clinics, cardiology service lines, sleep medicine, orthopedics, bariatric surgery, pharmacy and chronic disease management have all grown inside a system where obesity was widespread, persistent and often untreated.
GLP-1s may be starting to upend that model as the growing use of obesity drugs begin to influence utilization patterns, hospital economics, pharmaceutical R&D and long-term healthcare spending, wrote Robin Wenzel, head of Wells Fargo Industry Insights and John Teasley, market executive, Wells Fargo Healthcare Banking, in the report.
The latest data from the Centers for Disease Control and Prevention and National Center for Health Statistics indicates that 40.3% of U.S. adults have obesity, and 9.4%, roughly one in ten, have severe obesity. That makes obesity not an outlier, but a baseline condition around which much of U.S. healthcare now operates, the report authors assert.
GLP-1 drugs for weight management move the management of obesity upstream, to prevention in the context of a system designed around late-stage disease. That puts traditional obesity-related service lines, and healthcare's obesity revenue engine, under pressure, according to the report.
Surgery remains one of the most effective and durable interventions for severe obesity, but data suggests patient behavior is already shifting. A 2026 Journal of the American Medical Association (JAMA) surgery analysis found that metabolic bariatric surgery volumes fell 34.1% from 2022 to 2024, even as GLP-1 use rose more than 140% over the same period.
As the use of GLP-1 drugs for weight loss continues to grow, there will be downstream impacts to cardiology service lines and chronic disease management as well, the report notes.
The Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity (SELECT) trial showed that semaglutide reduced major adverse cardiovascular events by 20% in overweight or obese adults without diabetes.
"If GLP-1s reduce cardiovascular events in high-risk populations at scale, the impact to hospitals is not only fewer procedures, it is fewer repeat admissions, complications, and downstream interventions. For service lines built on those events, that is a sizable reduction in demand," the report authors wrote.
As GLP-1s demonstrate the ability to prevent costly complications, health systems may need to rethink service lines built around treating them.
As acute interventions decline, care shifts toward longitudinal management, outpatient visits, medication management, side-effect monitoring and long-term adherence support. It's expected that this will drive greater demand for obesity medicine, specialty pharmacy, medication adherence support and integrated cardiometabolic care, the report authors noted.
Care may also shift to focus on the comorbidities that obesity drives, from orthopedic procedures such as knee and hip replacement to obstructive sleep apnea and metabolic (MASH) liver disease.
The downstream impact to areas like orthopedics remains uncertain because weight loss could both reduce complications and expand the pool of patients eligible for surgery. Stryker, the world’s largest orthopedic device manufacturer, has argued that GLP-1s are a net neutral to slightly positive: by helping obese patients slim down to qualify for surgery, the drugs may unlock previously ineligible candidates and expand the patient pool.
Researchers also have posited that patients still on GLP-1 therapy who become more active after weight loss will see joint wear accelerate, potentially pulling forward arthroplasty demand.
"The net effect on procedure volumes will likely depend on adoption rates, drug persistence and how surgeons update BMI-based eligibility thresholds, questions the data has not yet resolved. For orthopedic device makers and hospital service lines, the opportunity lies with the obesity-arthroplasty pipeline being restructured, not simply compressed," the report authors wrote.
The long-term impact of GLP-1 use paints a complicated financial picture for the healthcare industry. A 2024 JAMA Network Open analysis estimated that weight loss among overweight or obese adults is associated with lower healthcare spending, with the largest reductions at higher levels of weight loss.
But GLP-1 drugs are creating significant near-term drug costs for employers, payers and Medicare.
About 64% of large firms say covering GLP-1s for weight loss has moderately or significantly increased their prescription-drug spending, according to Peterson-KFF Health System Tracker data, and gross Medicare Part D spending on GLP-1s reached $27.5 billion in 2024, a five fold increase since 2019, even before coverage for obesity is broadly authorized.
For hospitals and health plans, the near-term cost pressure is real even if long-run utilization of acute services declines, the report notes.
The drug pipeline also is being rewritten. In its annual analysis of pharmaceutical R&D returns, Deloitte found that, for the first time in 16 years of analysis, obesity has displaced oncology as the largest contributor to late-stage pipeline value. Obesity assets, driven almost exclusively by GLP-1 and GLP-1/GIP molecules, now account for roughly 25% of forecast late-stage pipeline value, up from just 1% in 2022, as Fierce Pharma reported.
The next stage of GLP-1 costs may depend on public payers. The Congressional Budget Office estimates that authorizing Medicare to cover anti-obesity medications would increase federal spending by about $35 billion between 2026 and 2034, with the near-term cost per user, roughly $5,600 in 2026, far exceeding the offsetting federal savings from improved health, about $50 per user that year.
"The clinical benefits of weight loss would take several years to fully materialize as lower health care utilization but would still not fully offset the cost per user. The economics, in other words, hinge on price as much as on volume," the report authors wrote.
For investors, the implication is not that healthcare revenues decline, it is that profit centers move, the report authors wrote.
"The likely healthcare industry winners will not be those who defend the old model, but those who reposition ahead of it, reallocating capital and talent toward obesity medicine, integrated cardiometabolic care, and specialty pharmacy, while right-sizing the service lines GLP-1s will erode and absorbing the near-term cost of the drugs themselves. The strategic question is no longer whether obesity remains prevalent and profitable, but how quickly the ecosystem can rebuild its economics around prevention that finally works," the report authors wrote.